Liver Cancer Drugs Market Size, Share, Growth Analysis, By Type(Hepatocellular Carcinoma, Cholangiocarcinoma, and Hepatoblastoma), By Therapy(Targeted Drug Therapy, Immunotherapy, and Chemotherapy), By Service(Managed services, and professional services), By Deployment(Cloud and On-premise), By Region - Industry Forecast 2024-2031

Liver Cancer Drugs Market size was valued at USD 2.7 Billion in 2022 and is poised to grow from USD 3.18 Billion in 2023 to USD 11.6 Billion by 2031, growing at a CAGR of 17.6% in the forecast period (2024-2031).

The availability of novel drugs, the presence of strong pipelines, and rising public awareness are among the key trends escalating market growth. Besides this, growing incidence of liver cancer due to increasing geriatric population and unorganized lifestyle is estimated to provide a fillip to the market. Hepatocellular carcinomas (HCCs) account for the majority (75–90%) of primary liver cancers. A significant number of etiological factors of liver cancer, including hepatitis infection and cirrhosis, are modifiable and present a strong prospect to reduce its incidence and mortality by preventive strategies such as lifestyle modification and hepatitis immunization.

North America and Southern Europe have the highest incidence of mortality ratios for liver cancer. Incidence rates varied geographically, with the highest incidence rates for males recorded in Eastern Asia (31.9 per 100,000) and South-Eastern Asia (22.2 per 100,000). The highest incidence rates for females were reported in Eastern Asia (10.2 per 100,000) and Western Africa (8.1 per 100,000)

US Liver Cancer Drugs Market is poised to grow at a sustainable CAGR for the next forecast year.